ORKA

SEC filing ORKA Amends IL-23 License Agreement with Paragon, Expands Field to Include All Therapeutic Uses with Certain Restrictions on ORKA-001 Trials

20h ago

Insider trade Sale by Dambkowski Carl

10d ago

Insider trade Sale by Agarwal Arjun (Senior Vice President, Finance)

14d ago

Insider trade Sale by Goncalves Joana (Chief Medical Officer)

17d ago

News A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?

21d ago

Insider trade Sale by Laura Lee Sandler (Chief Operating Officer)

31d ago

News Oruka Therapeutics prices upsized $700M public offering at $72.50 per share

34d ago

News Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

35d ago

SEC filing ORKA Reports $0 Revenue, $0 EPS, +0% YoY; ORKA-001 Achieves 63.5% PASI 100 at Week 16; Conference Call Today 8:00 a.m. ET; Phase 1 PK/PD Supports Annual Dosing; Longer-Term Data Expected 2H 2026

36d ago

Insider trade Sale by Joana Goncalves (Chief Medical Officer)

47d ago

Insider trade Sale by Lawrence Otto Klein (Chief Executive Officer)

76d ago

Insider trade Sale by Arjun Agarwal (Senior Vice President, Finance)

76d ago

Insider trade Sale by Laura Lee Sandler (Chief Operating Officer)

76d ago

Insider trade Sale by Joana Goncalves (Chief Medical Officer)

76d ago

Insider trade Sale by Paul T Quinlan (General Counsel)

76d ago

Insider trade Sale by Laura Lee Sandler (Chief Operating Officer)

91d ago

Insider trade Sale by Joana Goncalves (Chief Medical Officer)

104d ago

Insider trade Sale by Joana Goncalves

104d ago

Insider trade Sale by Sandler Laura Lee (Chief Operating Officer)

150d ago

Scanner Unusual volume (z=18.6)

160d ago

Scanner Unusual volume (z=18.9)

161d ago

Scanner Unusual volume (z=18.9)

163d ago

Scanner Unusual volume (z=18.9)

164d ago